Susan Samson, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1790899227
Payments from drug & device makers
Across 41 payments — averaging $900.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$15K
- OPKO Pharmaceuticals, LLC$12K
- Corcept Therapeutics$5K
- Novartis$4K
- Chiesi USA, Inc.$1K
- Pfizer$131
- plus $72 from 3 others
Across 9 payments — averaging $370.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$18,56078%
- Travel & lodging$3,83116%
- Food & beverage$1,4686%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $14,840 |
| OPKO Pharmaceuticals, LLC | 1 | $12,246 |
| Corcept Therapeutics | 15 | $4,556 |
| Novartis | 2 | $3,968 |
| Chiesi USA, Inc. | 7 | $1,128 |
| Pfizer | 2 | $131 |
| Xeris Pharmaceuticals, Inc. | 1 | $43 |
| Shire North American Group Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$14,280
- Korlym$4,114
- SIGNIFOR$3,150
- MYCAPSSA$999
How this compares
$36,939 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 12 | $256,795 |
| Norditropin FlexproSomatropin | 14 | $47,083 |
| Testosterone | 28 | $6,145 |
| Cabergoline | 30 | $2,140 |
| Hydrocortisone | 50 | $1,952 |
| Testosterone Cypionate | 28 | $654 |
| Levothyroxine Sodium | 52 | $377 |
| Liothyronine Sodium | 11 | $314 |
| Prednisone | 16 | $181 |
| Dexamethasone | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Senan SultanJacksonville$2.5M
- J EvansJacksonville$1.7M
- Wasim DeebJacksonville$1.5M
- Ricardo SilvaJacksonville$867K
- Anil ShresthaJacksonville$602K
- Joe ChehadeJacksonville$542K
- Firas WardaJacksonville$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.